Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Pharm-country entities : Merck & company, inc. save search
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy (CRT) Significantly Improved Overall Survival (OS) Versus CRT Alone in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer
Published: 2024-03-15 (Crawled : 11:00) - biospace.com/
MRK | $126.57 -0.24% 950K
|
Health Technology
|
| O: -0.56%
H: 1.75%
C: 1.4%
keytruda cancer alone advanced plus
Merck Completes Acquisition of Harpoon Therapeutics, Inc.
Published: 2024-03-11 (Crawled : 16:00) - biospace.com/
MRK | $126.57 -0.24% 950K
|
Health Technology
|
| O: 0.93%
H: 0.0%
C: -1.51%
merck acquisition
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy for New First-Line Indications in Advanced HER2-Negative Gastric or GEJ Adenocarcinoma in Tumors
Published: 2023-12-18 (Crawled : 14:00) - biospace.com/
MRK | $126.57 -0.24% 950K
|
Health Technology
|
| O: 1.0%
H: 0.99%
C: -0.11%
keytruda tumors advanced plus
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Gemcitabine and Cisplatin as First-Line Treatment for Locally Advanced Unresectable or Metastatic Biliary Tract Cancer
Published: 2023-11-10 (Crawled : 14:00) - biospace.com/
MRK | $126.57 -0.24% 950K
|
Health Technology
|
| O: 0.45%
H: 0.51%
C: -1.41%
keytruda chmp merck positive cancer treatment plus gemcitabine
Merck Announces Third-Quarter 2023 Financial Results
Published: 2023-10-26 (Crawled : 11:00) - biospace.com/
MRK | $126.57 -0.24% 950K
|
Health Technology
|
| O: -0.51%
H: 4.0%
C: 2.38%
SNY | News | $47.27 -0.88% 130K
|
Health Technology
|
| O: 0.09%
H: 0.0%
C: 0.0%
MRNA | News S | $109.98 1.94% 1.3M
|
Health Technology
|
| O: -0.04%
H: 0.64%
C: -0.98%
merck financial results
Merck Presents New Analyses Supporting the Promising Potential of Sotatercept, its Investigational Medicine for Adults with Pulmonary Arterial Hypertension (PAH)
Published: 2023-09-11 (Crawled : 12:30) - biospace.com/
MRK | $126.57 -0.24% 950K
|
Health Technology
|
| O: 0.25%
H: 0.11%
C: -0.66%
merck hypertension potential
Moderna and Merck Announce mRNA-4157 (V940) in Combination With KEYTRUDA(R) (pembrolizumab)
Published: 2023-06-05 (Crawled : 13:00) - biospace.com/
MRK | $126.57 -0.24% 950K
|
Health Technology
|
| O: 0.43%
H: 1.31%
C: 0.1%
MRNA | News S | $109.98 1.94% 1.3M
|
Health Technology
|
| O: 0.38%
H: 2.74%
C: -1.6%
rna-4157 merck
FDA Approves LYNPARZA® (olaparib) Plus Abiraterone and Prednisone or Prednisolone for Treatment of Adult Patients With BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Published: 2023-06-01 (Crawled : 12:20) - biospace.com/
MRK | $126.57 -0.24% 950K
|
Health Technology
|
| O: 0.23%
H: 0.84%
C: 0.24%
lynparza fda cancer treatment plus
Merck and Eisai Provide Update on Phase 3 Trials of KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) In Certain Patients With Advanced Melanoma (LEAP-003) and Metastatic Colorectal Cancer (LEAP-017)
Published: 2023-04-07 (Crawled : 12:00) - biospace.com/
MRK | $126.57 -0.24% 950K
|
Health Technology
| Email alert
Add to watchlist
leap-003 keytruda melanoma merck update cancer trials plus
Merck’s Investigational Activin Signaling Inhibitor Sotatercept Improved Six-Minute Walk Distance by 40.8 Meters at Week 24 Versus Placebo in Adults with Pulmonary Arterial Hypertension on Background Therapy
Published: 2023-03-06 (Crawled : 21:00) - biospace.com/
MRK | $126.57 -0.24% 950K
|
Health Technology
|
| O: 0.73%
H: 3.33%
C: 3.2%
hypertension week therapy
Merck’s MK-0616, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Patients with Hypercholesterolemia in Phase 2b Study
Published: 2023-03-06 (Crawled : 21:00) - biospace.com/
MRK | $126.57 -0.24% 950K
|
Health Technology
|
| O: 0.73%
H: 3.33%
C: 3.2%
mk-0616 study hypercholesterolemia
Merck Announces Phase 3 KEYNOTE-671 Trial Met Primary Endpoint of Event-Free Survival (EFS) in Patients With Resectable Stage II, IIIA or IIIB Non-Small Cell Lung Cancer
Published: 2023-03-01 (Crawled : 12:00) - biospace.com/
MRK | $126.57 -0.24% 950K
|
Health Technology
|
| O: -0.26%
H: 1.5%
C: 0.65%
ynote-671 lung trial cancer
Merck Opens Enrollment in New Phase 3 Clinical Trials with Investigational Once-Daily Islatravir in Combination with Doravirine for Treatment of HIV-1 Infection
Published: 2023-02-22 (Crawled : 13:00) - biospace.com/
MRK | $126.57 -0.24% 950K
|
Health Technology
|
| O: 1.05%
H: 0.1%
C: -0.95%
treatment trials infection hiv
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy Alone in Patients With HER2-Negative Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Regardless of PD-L1 Expression
Published: 2023-02-16 (Crawled : 18:00) - biospace.com/
MRK | $126.57 -0.24% 950K
|
Health Technology
|
| O: -0.8%
H: 0.6%
C: -0.29%
keytruda plus her2
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Met Primary Endpoint of Progression-Free Survival (PFS) as First-Line Therapy for Advanced or Recurrent Endometrial Carcinoma
Published: 2023-02-03 (Crawled : 14:20) - biospace.com/
MRK | $126.57 -0.24% 950K
|
Health Technology
|
| O: -0.23%
H: 0.55%
C: -0.27%
keytruda plus therapy
Merck Announces Fourth-Quarter and Full-Year 2022 Financial Results
Published: 2023-02-02 (Crawled : 14:00) - biospace.com/
ALPMY | News | $9.49 480K
|
Manufacturing
|
| O: 1.22%
H: 0.0%
C: -1.61%
MRK | $126.57 -0.24% 950K
|
Health Technology
|
| O: -2.77%
H: 1.72%
C: -0.54%
SGEN | $228.74 0.1% 20M
|
Health Technology
|
| O: -0.37%
H: 1.07%
C: 0.66%
SNY | News | $47.27 -0.88% 130K
|
Health Technology
|
| O: -1.44%
H: 0.0%
C: 0.0%
MRNA | News S | $109.98 1.94% 1.3M
|
Health Technology
|
| O: -0.52%
H: 1.92%
C: 1.7%
financial results
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy in First-Line Advanced or Unresectable Biliary Tract Cancer in KEYNOTE-966 Trial
Published: 2023-01-25 (Crawled : 12:00) - biospace.com/
MRK | $126.57 -0.24% 950K
|
Health Technology
|
| O: 0.18%
H: 1.12%
C: -0.11%
ynote-966 keytruda trial plus cancer
Merck Announces KEYNOTE-991 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Enzalutamide and Androgen Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer to Stop for Futility
Published: 2023-01-25 (Crawled : 12:00) - biospace.com/
MRK | $126.57 -0.24% 950K
|
Health Technology
|
| O: 0.18%
H: 1.12%
C: -0.11%
ynote-991 keytruda trial plus therapy cancer prostate cancer
Merck Begins Tender Offer to Acquire Imago BioSciences, Inc.
Published: 2022-12-12 (Crawled : 12:00) - biospace.com/
IMGO | $36.01 0.03% 0.0% 0
|
Health Technology
|
| O: 0.01%
H: 0.15%
C: -0.11%
MRK | $126.57 -0.24% 950K
|
Health Technology
|
| O: -0.78%
H: 1.08%
C: 0.96%
acquire
Merck Announces Phase 3 KEYNOTE-859 Trial Met Primary Endpoint of Overall Survival in Patients With HER2-Negative Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Published: 2022-11-22 (Crawled : 12:20) - biospace.com/
MRK | $126.57 -0.24% 950K
|
Health Technology
|
| O: 0.49%
H: 0.92%
C: 0.73%
ynote-859 trial her2- her2
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
CZOO | $11.44 129.26% 4.6M
|
AMST | $3.4 70.0% 51M
|
Technology Services
BOF | $1.78 52.14% 15M
|
SYRA | $1.5 51.23% 1M
|
n/a
CSSE 4 | $0.23 51.02% 46M
|
Consumer Services
RILY | $30.87 42.13% 7.8M
|
Finance
LICN | $0.76 35.71% 6.2M
|
TROO | $1.41 29.36% 280K
|
Manufacturing
MULN | News | $3.53 29.3% 4.8M
|
Information
RBBN 4 | $3.26 26.85% 1.2M
|
Electronic Technology
Your saved searches
Save your searches and get alerts when important news are released.